Clinical trial
A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer - Norwegian Pancreatic Cancer Trial-3 (NORPACT 3)
NCT06944587 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer - Norwegian Pancreatic Cancer Trial-3 (NORPACT 3)
- Lead sponsor
- Oslo University Hospital
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- December 3, 2024
- Completion date
- December 31, 2028
- Enrollment
- 400 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
borderline resectable pancreatic cancer, chemotherapy effect, locally advanced pancreatic cancer, pancreatectomy